Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
Report Scope:
The scope of this study encompasses the global and regional markets for Alzheimer’s therapeutics and diagnostics. These markets are segmented by branded and generic drugs, and mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (A?) vaccines. Drugs are also segmented by the stage of Alzheimer’s disease they treat, i.e., mild to moderate, severe and prodromal.
BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe, Asia-Pacific and Rest of the world (RoW).
Report Includes:
The scope of this study encompasses the global and regional markets for Alzheimer’s therapeutics and diagnostics. These markets are segmented by branded and generic drugs, and mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (A?) vaccines. Drugs are also segmented by the stage of Alzheimer’s disease they treat, i.e., mild to moderate, severe and prodromal.
BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe, Asia-Pacific and Rest of the world (RoW).
Report Includes:
- 27 tables
- An overview of the global market for Alzheimer's disease (AD) therapeutics and diagnostics
- Estimation of the market size and analyses of global market trends with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Detailed description of Alzheimer's disease and discussion on disease-related events, etiology and epidemiology covering prevalence and incidence rates
- Identification of diagnostic tools and equipment; evaluation of important scientific and technological frameworks; and coverage of developments in the global market for Alzheimer's disease therapeutics and diagnostics.
- Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease as well as highlights of the promising new drug candidates and diagnostic imaging agents
- Market share analysis of Alzheimer's disease therapeutics and diagnostics, by mechanism of action, disease stage and major geographical regions covering North America, Europe, APAC and Rest of the World
- Detailed analysis of the current market trends, market forecast, drivers, challenges, and opportunities affecting market growth and discussion on regulatory and competitive elements that are affecting the future marketplace
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Company profiles of major market players, including AbbVie, AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Pfizer Inc., Novartis and Sanofi
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 OVERVIEW
Alzheimer's Disease: Definition and Market Structure
Alzheimer's Disease Pathophysiology
AD and Amyloid Cascade
AD and Tauopathy
AD and Neurotransmitter Systems
Alzheimer's Disease Etiology
Genetic Factors
Non-Genetic Factors
Alzheimer's Disease Epidemiology
Age of Onset
Incidence, Prevalence and Mortality
Stages and Severity of AD
Comorbidities
Diagnosis and Treatment of Alzheimer's
Diagnosis of Alzheimer's
Companion Imaging Diagnostics for AS
CIDX Technologies for Amyloid Visualization
CIDX Technologies for TAU-NFT Visualization
Comparative Analysis of Tau Tracers in Development
CIDX Technologies: A? vs. Tau Imaging Technologies
Concluding Remarks
Pharmaceutical Treatment of AD
CHAPTER 4 REGULATORY STRUCTURE
U.S.
Accelerated Approvals
Fast Track Designation
Breakthrough Therapy Designation
Priority Review
Controlled Substances Act
Special Protocol Assessments
New Surveillance and Safety Requirements
Canada
Mexico
Europe
Asia-Pacific
Rest of the World
Reimbursement Landscape
CHAPTER 5 MARKET DYNAMICS
Market Drivers
Use of Biomarkers in Diagnosis and Drug Development
Large Number of Drugs in the Pipeline
Market Restraints
Patent Expirations of Branded Drugs and Emergence of Generics
High Failure Rate in Drug Development
High Cost of Drug Development
CHAPTER 6 GLOBAL MARKETS FOR ALZHEIMER'S DISEASE THERAPEUTICS
Market Overview
Global Market for Alzheimer's Drugs by Mechanism of Action
Acetylcholinesterase Inhibitors (AChEIs)
NMDA Drugs
Global Market for Branded/Generic AD Therapeutics by Type
Global Market for AD Therapeutics by Stage of AD
CHAPTER 7 MARKET BREAKDOWN BY REGION
Global Market for Alzheimer's Drugs by Region
North America
Europe
Asia-Pacific
Rest of the World
Industry Structure
Impact of Generic AD Therapeutics
CHAPTER 8 PIPELINE ANALYSIS
Overview of the Drug Development Process
Phase III
Phase II
Phase I
Trial Sponsors
CHAPTER 9 COMPANY PROFILES
ABBVIE
ACADIA PHARMACEUTICALS INC.
ALEMBIC PHARMACEUTICALS LTD.
ALEXZA PHARMACEUTICALS
ALKERMES PLC
ALLERGAN PLC
APOTEX INC.
ASTRAZENECA PLC
AUROBINDO PHARMA
AVANIR PHARMACEUTICALS INC.
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB CO.
BIOGEN
DAIICHI SANKYO CO., LTD.
DR. REDDY'S LABORATORIES LTD.
ELI LILLY AND CO.
EISAI CO., LTD.
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
GEDEON RICHTER PLC
IMMUNOCELLULAR THERAPEUTICS LTD.
JOHNSON & JOHNSON
LANNETT CO., INC.
H. LUNDBECK A/S
LUPIN LTD.
MALLINCKRODT
MERCK & CO.
MYLAN NV
NEXTSOURCE BIOTECHNOLOGY LLC
NOVARTIS AG
OTSUKA HOLDINGS CO., LTD.
PFIZER INC.
SANOFI
SUMITOMO DAINIPPON PHARMA CO., LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
TORRENT PHARMACEUTICALS LTD.
UCB SA
CHAPTER 10 APPENDIX: ACRONYMS
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 OVERVIEW
Alzheimer's Disease: Definition and Market Structure
Alzheimer's Disease Pathophysiology
AD and Amyloid Cascade
AD and Tauopathy
AD and Neurotransmitter Systems
Alzheimer's Disease Etiology
Genetic Factors
Non-Genetic Factors
Alzheimer's Disease Epidemiology
Age of Onset
Incidence, Prevalence and Mortality
Stages and Severity of AD
Comorbidities
Diagnosis and Treatment of Alzheimer's
Diagnosis of Alzheimer's
Companion Imaging Diagnostics for AS
CIDX Technologies for Amyloid Visualization
CIDX Technologies for TAU-NFT Visualization
Comparative Analysis of Tau Tracers in Development
CIDX Technologies: A? vs. Tau Imaging Technologies
Concluding Remarks
Pharmaceutical Treatment of AD
CHAPTER 4 REGULATORY STRUCTURE
U.S.
Accelerated Approvals
Fast Track Designation
Breakthrough Therapy Designation
Priority Review
Controlled Substances Act
Special Protocol Assessments
New Surveillance and Safety Requirements
Canada
Mexico
Europe
Asia-Pacific
Rest of the World
Reimbursement Landscape
CHAPTER 5 MARKET DYNAMICS
Market Drivers
Use of Biomarkers in Diagnosis and Drug Development
Large Number of Drugs in the Pipeline
Market Restraints
Patent Expirations of Branded Drugs and Emergence of Generics
High Failure Rate in Drug Development
High Cost of Drug Development
CHAPTER 6 GLOBAL MARKETS FOR ALZHEIMER'S DISEASE THERAPEUTICS
Market Overview
Global Market for Alzheimer's Drugs by Mechanism of Action
Acetylcholinesterase Inhibitors (AChEIs)
NMDA Drugs
Global Market for Branded/Generic AD Therapeutics by Type
Global Market for AD Therapeutics by Stage of AD
CHAPTER 7 MARKET BREAKDOWN BY REGION
Global Market for Alzheimer's Drugs by Region
North America
Europe
Asia-Pacific
Rest of the World
Industry Structure
Impact of Generic AD Therapeutics
CHAPTER 8 PIPELINE ANALYSIS
Overview of the Drug Development Process
Phase III
Phase II
Phase I
Trial Sponsors
CHAPTER 9 COMPANY PROFILES
ABBVIE
ACADIA PHARMACEUTICALS INC.
ALEMBIC PHARMACEUTICALS LTD.
ALEXZA PHARMACEUTICALS
ALKERMES PLC
ALLERGAN PLC
APOTEX INC.
ASTRAZENECA PLC
AUROBINDO PHARMA
AVANIR PHARMACEUTICALS INC.
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB CO.
BIOGEN
DAIICHI SANKYO CO., LTD.
DR. REDDY'S LABORATORIES LTD.
ELI LILLY AND CO.
EISAI CO., LTD.
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
GEDEON RICHTER PLC
IMMUNOCELLULAR THERAPEUTICS LTD.
JOHNSON & JOHNSON
LANNETT CO., INC.
H. LUNDBECK A/S
LUPIN LTD.
MALLINCKRODT
MERCK & CO.
MYLAN NV
NEXTSOURCE BIOTECHNOLOGY LLC
NOVARTIS AG
OTSUKA HOLDINGS CO., LTD.
PFIZER INC.
SANOFI
SUMITOMO DAINIPPON PHARMA CO., LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
TORRENT PHARMACEUTICALS LTD.
UCB SA
CHAPTER 10 APPENDIX: ACRONYMS
LIST OF TABLES
Summary Table: Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 1: Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Table 2: Pharmacological Treatment of BPSD of Alzheimer's
Table 3: Computerized Screening Tests Used in Detecting Cognitive Impairment
Table 4: Brain Imaging Technologies and Application in the Alzheimer's Context
Table 5: Global Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 6: Global Market for Alzheimer's AChEIs Drugs, by Region, Through 2025
Table 7: Global Market for Alzheimer's NMDA Drugs , by Region, Through 2025
Table 8: Global Market for Alzheimer's Drugs, by Type, Through 2025
Table 9: Global Market for AD Therapeutics, by Disease Stage, Through 2025
Table 10: Global Market for Late Stage/Severe AD Therapeutics, by Region, Through 2025
Table 11: Global Market for Early/Middle Stage AD Therapeutics, by Region, Through 2025
Table 12: Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 13: North American Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 14: North American Market for Alzheimer's Drugs, by Country, Through 2025
Table 15: North American Market for Alzheimer's Drugs, by Type, Through 2025
Table 16: European Market for Alzheimer's Drugs, by Country, Through 2025
Table 17: European Market for Alzheimer's Drugs, by Type, Through 2025
Table 18: European Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 19: Asia-Pacific Market for Alzheimer's Drugs, by Type, Through 2025
Table 20: Asia-Pacific Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 21: Global Ranking of Leading Players in Alzheimer's Disease Drugs
Table 22: Agents in Phase III of Alzheimer's Disease Drug Development
Table 23: Agents in Phase II of Alzheimer's Disease Drug Development
Table 24: Agents in Phase I of Alzheimer's Disease Drug Development
Table 25: Trial Sponsor for Each Phase of Alzheimer's Disease Drug Development
Table 26: Acronyms Used in This Report
Summary Table: Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 1: Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Table 2: Pharmacological Treatment of BPSD of Alzheimer's
Table 3: Computerized Screening Tests Used in Detecting Cognitive Impairment
Table 4: Brain Imaging Technologies and Application in the Alzheimer's Context
Table 5: Global Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 6: Global Market for Alzheimer's AChEIs Drugs, by Region, Through 2025
Table 7: Global Market for Alzheimer's NMDA Drugs , by Region, Through 2025
Table 8: Global Market for Alzheimer's Drugs, by Type, Through 2025
Table 9: Global Market for AD Therapeutics, by Disease Stage, Through 2025
Table 10: Global Market for Late Stage/Severe AD Therapeutics, by Region, Through 2025
Table 11: Global Market for Early/Middle Stage AD Therapeutics, by Region, Through 2025
Table 12: Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 13: North American Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 14: North American Market for Alzheimer's Drugs, by Country, Through 2025
Table 15: North American Market for Alzheimer's Drugs, by Type, Through 2025
Table 16: European Market for Alzheimer's Drugs, by Country, Through 2025
Table 17: European Market for Alzheimer's Drugs, by Type, Through 2025
Table 18: European Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 19: Asia-Pacific Market for Alzheimer's Drugs, by Type, Through 2025
Table 20: Asia-Pacific Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 21: Global Ranking of Leading Players in Alzheimer's Disease Drugs
Table 22: Agents in Phase III of Alzheimer's Disease Drug Development
Table 23: Agents in Phase II of Alzheimer's Disease Drug Development
Table 24: Agents in Phase I of Alzheimer's Disease Drug Development
Table 25: Trial Sponsor for Each Phase of Alzheimer's Disease Drug Development
Table 26: Acronyms Used in This Report
LIST OF FIGURES
Summary Figure: Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 1: Trends in Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Figure 2: Pharmaceutical Regulatory Pathways in the U.S. and Europe
Figure 3: Global Market for Alzheimer's AChEIs Drugs, 2019-2025
Figure 4: Global Market for Alzheimer's NMDA Drugs, 2019-2025
Figure 5: Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 6: North American Market for Alzheimer's Drugs, 2019-2025
Figure 7: European Market for Alzheimer's Drugs, 2019-2025
Figure 8: Asia-Pacific Market for Alzheimer's Drugs, 2019-2025
Figure 9: South American Market for Alzheimer's Drugs, 2019-2025
Figure 10: Middle Eastern and African Market for Alzheimer's Drugs, 2019-2025
Summary Figure: Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 1: Trends in Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Figure 2: Pharmaceutical Regulatory Pathways in the U.S. and Europe
Figure 3: Global Market for Alzheimer's AChEIs Drugs, 2019-2025
Figure 4: Global Market for Alzheimer's NMDA Drugs, 2019-2025
Figure 5: Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 6: North American Market for Alzheimer's Drugs, 2019-2025
Figure 7: European Market for Alzheimer's Drugs, 2019-2025
Figure 8: Asia-Pacific Market for Alzheimer's Drugs, 2019-2025
Figure 9: South American Market for Alzheimer's Drugs, 2019-2025
Figure 10: Middle Eastern and African Market for Alzheimer's Drugs, 2019-2025
